Your browser doesn't support javascript.
loading
Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
Pagel, John M; Matthews, Dana C; Kenoyer, Aimee; Hamlin, Donald K; Wilbur, Daniel S; Fisher, Darrell R; Gopal, Ajay K; Lin, Yukang; Saganic, Laura; Appelbaum, Frederick R; Press, Oliver W.
Afiliación
  • Pagel JM; Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., Seattle, WA 98109, USA. jpagel@fhcrc.org
Cancer Res ; 69(1): 185-92, 2009 Jan 01.
Article en En | MEDLINE | ID: mdl-19118002
ABSTRACT
Radioimmunotherapy (RIT) for treatment of hematologic malignancies frequently fails because of disease recurrence. We therefore conducted pretargeted (P)RIT studies to augment the efficacy in mice of therapy using a pretargeted anti-human (h)CD45 antibody (Ab)-streptavidin (SA) conjugate followed by a biotinylated clearing agent and radiolabeled 1,4,7,10-tetraazacylodode cane N,N',N",N'''-tetraacetic (DOTA)-biotin. Tumor-to-blood ratios at 24 hours were 201 using pretargeted anti-hCD45 RIT and <11 with conventional RIT. In vivo imaging studies confirmed that the PRIT approach provided high-contrast tumor images with minimal blood-pool activity, whereas directly labeled anti-hCD45 Ab produced distinct tumor images but the blood pool retained a large amount of labeled Ab for a prolonged time. Therapy experiments showed that (90)Y-DOTA-biotin significantly prolonged survival of mice treated with pretargeted anti-hCD45 Ab-SA compared with mice treated with conventional RIT using (90)Y-labeled anti-hCD45 Ab at 200 muCi. Because human CD45 antigens are confined to xenograft tumor cells in this model, and all murine tissues are devoid of hCD45 and will not bind anti-hCD45 Ab, we also compared one-step and PRIT using an anti-murine (m)CD45 Ab where the target antigen is present on normal hematopoietic tissues. After 24 h, 27.3% +/- 2.8% of the injected dose of activity was delivered per gram (% ID/g) of lymph node using (131)I-A20-Ab compared with 40.0 +/- 5.4% ID/g for pretargeted (111)In-DOTA-biotin. These data suggest that pretargeted methods for delivering RIT may be superior to conventional RIT when targeting CD45 for the treatment of leukemia and may allow for the intensification of therapy, while minimizing toxicities.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Radioisótopos de Itrio / Leucemia Mieloide / Inmunotoxinas / Radioinmunoterapia / Antígenos Comunes de Leucocito / Anticuerpos Monoclonales Idioma: En Revista: Cancer Res Año: 2009 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Radioisótopos de Itrio / Leucemia Mieloide / Inmunotoxinas / Radioinmunoterapia / Antígenos Comunes de Leucocito / Anticuerpos Monoclonales Idioma: En Revista: Cancer Res Año: 2009 Tipo del documento: Article